- Home
- NVNO vs ERNA Comparison
NVNO vs ERNA Comparison
Compare NVNO & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- ERNA
- Stock Information
- Founded
- NVNO 1987
- ERNA 2018
- Country
- NVNO United States
- ERNA United States
- Employees
- NVNO N/A
- ERNA N/A
- Industry
- NVNO Medical/Dental Instruments
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- NVNO Health Care
- ERNA Health Care
- Exchange
- NVNO Nasdaq
- ERNA Nasdaq
- Market Cap
- NVNO 59.4M
- ERNA 56.4M
- IPO Year
- NVNO N/A
- ERNA N/A
- Fundamental
- Price
- NVNO $3.30
- ERNA $0.56
- Analyst Decision
- NVNO
- ERNA
- Analyst Count
- NVNO 0
- ERNA 0
- Target Price
- NVNO N/A
- ERNA N/A
- AVG Volume (30 Days)
- NVNO 117.4K
- ERNA 134.6K
- Earning Date
- NVNO 10-31-2024
- ERNA 11-12-2024
- Dividend Yield
- NVNO N/A
- ERNA N/A
- EPS Growth
- NVNO N/A
- ERNA N/A
- EPS
- NVNO N/A
- ERNA N/A
- Revenue
- NVNO N/A
- ERNA $598,000.00
- Revenue This Year
- NVNO N/A
- ERNA N/A
- Revenue Next Year
- NVNO N/A
- ERNA N/A
- P/E Ratio
- NVNO N/A
- ERNA N/A
- Revenue Growth
- NVNO N/A
- ERNA 1072.55
- 52 Week Low
- NVNO $3.01
- ERNA $0.52
- 52 Week High
- NVNO $6.97
- ERNA $2.63
- Technical
- Relative Strength Index (RSI)
- NVNO 43.55
- ERNA 23.08
- Support Level
- NVNO $3.24
- ERNA $0.52
- Resistance Level
- NVNO $3.75
- ERNA $1.20
- Average True Range (ATR)
- NVNO 0.18
- ERNA 0.11
- MACD
- NVNO 0.02
- ERNA -0.05
- Stochastic Oscillator
- NVNO 12.62
- ERNA 5.53
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
About ERNA Eterna Therapeutics Inc.
Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.